Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Clinical trial NCT03682068 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03682068
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Unresectable Locally Advanced Urothelial Cancer Metastatic Urothelial Cancer

Start date: 2018-09-27
Primary completion: 2026-06-01
Enrollment: 1246

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.